COVID-19 induces a hyperactive phenotype in circulating platelets
Open Access
- 17 February 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Biology
- Vol. 19 (2), e3001109
- https://doi.org/10.1371/journal.pbio.3001109
Abstract
Coronavirus Disease 2019 (COVID-19), caused by the novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has affected over 30 million globally to date. Although high rates of venous thromboembolism and evidence of COVID-19-induced endothelial dysfunction have been reported, the precise aetiology of the increased thrombotic risk associated with COVID-19 infection remains to be fully elucidated. Therefore, we assessed clinical platelet parameters and circulating platelet activity in patients with severe and nonsevere COVID-19. An assessment of clinical blood parameters in patients with severe COVID-19 disease (requiring intensive care), patients with nonsevere disease (not requiring intensive care), general medical in-patients without COVID-19, and healthy donors was undertaken. Platelet function and activity were also assessed by secretion and specific marker analysis. We demonstrated that routine clinical blood parameters including increased mean platelet volume (MPV) and decreased platelet:neutrophil ratio are associated with disease severity in COVID-19 upon hospitalisation and intensive care unit (ICU) admission. Strikingly, agonist-induced ADP release was 30- to 90-fold higher in COVID-19 patients compared with hospitalised controls and circulating levels of platelet factor 4 (PF4), soluble P-selectin (sP-selectin), and thrombopoietin (TPO) were also significantly elevated in COVID-19. This study shows that distinct differences exist in routine full blood count and other clinical laboratory parameters between patients with severe and nonsevere COVID-19. Moreover, we have determined all COVID-19 patients possess hyperactive circulating platelets. These data suggest abnormal platelet reactivity may contribute to hypercoagulability in COVID-19 and confirms the role that platelets/clotting has in determining the severity of the disease and the complexity of the recovery path.Keywords
Funding Information
- Science Foundation Ireland (20/COV/0157)
This publication has 64 references indexed in Scilit:
- A novel and essential role for FcγRIIa in cancer cell–induced platelet activationBlood, 2014
- Dengue induces platelet activation, mitochondrial dysfunction and cell death through mechanisms that involve DC-SIGN and caspasesJournal of Thrombosis and Haemostasis, 2013
- Platelet signalling networks: Pathway perturbation demonstrates differential sensitivity of ADP secretion and fibrinogen bindingPlatelets, 2011
- HIV‐1 Tat‐induced platelet activation and release of CD154 contribute to HIV‐1‐associated autoimmune thrombocytopeniaJournal of Thrombosis and Haemostasis, 2010
- Thrombopoietin levels increased in patients with severe acute respiratory syndromeThrombosis Research, 2008
- Anticoagulant prophylaxis to prevent asymptomatic deep vein thrombosis in hospitalized medical patients: a systematic review and meta-analysisJournal of Thrombosis and Haemostasis, 2008
- Role of vascular cell adhesion molecules and leukocyte apoptosis in the lymphopenia and thrombocytopenia of patients with severe acute respiratory syndrome (SARS)Microbes and Infection, 2006
- Platelet sizeBlood Coagulation & Fibrinolysis, 1996
- Soluble form of P-selectin in plasma is elevated in acute lung injury.American Journal of Respiratory and Critical Care Medicine, 1995
- Guidelines on platelet function testing. The British Society for Haematology BCSH Haemostasis and Thrombosis Task Force.Journal of Clinical Pathology, 1988